Akums Drugs and Pharmaceuticals share news, announcements and annual reports
NSE: AKUMSBSE: 544222Pharmaceuticals & BiotechnologySmall Cap
Akums Drugs and Pharmaceuticals Limited · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Aug 2024 · Issue price ₹679
Last close ₹731.70down ₹9.35 (1.26%)BSE ₹731.90
Share price at the NSE close on 30 Oct 2026. Previous close ₹741.05.
30 Oct: open ₹750.00, high ₹755.00, low ₹722.75
52-week range of traded prices to 30 Oct 2026
₹409.30Low, 21 Jan 2026₹838.80High, 23 Sep 2026
- Next results date: the board meets on 2 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹11,517 Cr630th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 39.48
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 3.48
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.41%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 9.2%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 12.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.02
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 1,45,38149.5% delivered
Akums Drugs and Pharmaceuticals analyst meets
39 filed, newest first.
Oct 2026
28 Oct · Analysts
Sep 2026
23 Sep · Analysts
16 Sep · Analysts
Aug 2026
25 Aug · Analysts
13 Aug · Analysts
10 Aug · Analysts
5 Aug · Analysts
Jun 2026
10 Jun · Analysts
9 Jun · Analysts
3 Jun · Analysts
May 2026
28 May · Analysts
12 May · Analysts
Feb 2026
26 Feb · Analysts
16 Feb · Analysts
13 Feb · Analysts
Jan 2026
31 Jan · Analysts
Dec 2025
9 Dec · Analysts
Nov 2025
17 Nov · Analysts
14 Nov · Analysts
14 Nov · Analysts
10 Nov · Analysts
Sep 2025
17 Sep · Analysts
Aug 2025
26 Aug · Analysts
11 Aug · Analysts
11 Aug · Analysts
5 Aug · Analysts
May 2025
27 May · Analysts
22 May · Analysts
Mar 2025
4 Mar · Analysts
1 Mar · Analysts
Feb 2025
11 Feb · Analysts
3 Feb · Analysts
Nov 2024
12 Nov · Analysts
11 Nov · Analysts
5 Nov · Analysts
Aug 2024
23 Aug · Analysts